Cytokinetics Inc (CYTK) Q1 2026 Earnings Call Transcript
Cytokinetics reported a strong commercial debut for MYCorzo, generating $4.8 million in product revenue within the first nine weeks and securing an $11.9 million Bayer milestone payment. The drug saw rapid adoption, with over 425 prescribers and 70% of dispensed patients on paid prescriptions, while European approval paves the way for a German launch in Q2. Phase 3 Acacia HCM results showed aficamtin met both primary endpoints, delivering meaningful improvements in KCCQ scores and peak VO2. The company closed the quarter with $1.1 billion in cash and reaffirmed its 2026 expense guidance.
Adaptive Biotechnologies Corp (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies reported $277 million total revenue for 2025, a 55% year‑over‑year increase, driven by a 46% jump in MRD revenue to $212 million and a 43% rise in clonoSEQ test volume to 30,038. Average selling price per test climbed 17% to...
Fasting Opens a Metabolic Window that Favors Anti-Tumor Immunity
Short‑term fasting reshapes the tumor microenvironment by temporarily increasing intratumoral isoleucine, creating a metabolic niche that cytotoxic CD8⁺ T cells can exploit. The study by Chen et al. shows that a 16‑hour fast elevates isoleucine levels, enhancing T‑cell effector programs and...
Vertex Drops mRNA Cystic Fibrosis Program over 'Tolerability' Issues
Vertex Pharmaceuticals announced it is halting development of its mRNA‑based cystic fibrosis (CF) therapy after encountering tolerability and delivery challenges. The decision follows similar setbacks at other biotech firms pursuing mRNA treatments for CF. Vertex will refocus resources on its...
Philip Ashton-Rickardt: From Lab to Biotech Leadership
Philip Ashton‑Rickardt, a former immunology professor, has become a serial biotech builder, founding Smith Therapeutics in 2017 and later steering its CAR‑Treg assets into AZTherapies. He then served as chief scientific officer at Sigilon Therapeutics, guiding a 50‑person research team...
Blood Stem Cells Evade Immune Attack in Aplastic Anemia Through Gene Mutations
Scientists at St. Jude Children’s Research Hospital analyzed 619 aplastic anemia patients and discovered that multiple independent gene mutations in blood stem cells silence the disease‑triggering HLA risk allele, allowing those cells to evade autoimmune attack. Overall, 69% of patients...
FDA Expectations Create Potential Friction in New Form 483 Response Guidance
The FDA has issued a draft guidance outlining heightened expectations for Form 483 response submissions, emphasizing greater detail and faster turnaround. Cooley’s life‑sciences regulatory chair, Sonia Nath, warned that these demands could generate friction between regulators and manufacturers. She urged...
Magnesium Supplementation Cuts Early Colorectal Cancer Risk in New Trial
Researchers at Vanderbilt University Medical Center reported that a 12‑week, personalized magnesium glycinate regimen reduced early signs of colorectal cancer in 240 adults with prior polyps. The supplement reshaped gut microbes to produce vitamin D locally, offering a novel, non‑sunlight‑dependent...
WSJ Calls Trump’s FDA Pick Marty Makary a Potential Disaster for Drug Approvals
The Wall Street Journal warned Sunday that President Donald Trump’s FDA nominee, surgeon‑scientist Dr. Marty Makary, could become a disaster for the agency. The editorial cites Makary’s pattern of blocking rare‑disease and gene‑therapy drugs, alleged conflicts of interest, and a...
Leroy Hood Unveils Dark Proteome Frontier at SynBioBeta 2026
“I am interested in deciphering human complexity in terms of wellness and disease. I guess you would describe me as a multi-disciplinary human biologist.” That is Dr. Lee Hood @ISBLeeHood in one quote. We're excited and honored to have Dr. Leroy Hood...
Israeli Team to Perform First Nanotech Spinal‑Cord Implant in Human Trial
Professor Tal Dvir of Tel Aviv University will lead the world’s first human implantation of a nanotech‑enhanced spinal‑cord scaffold, slated for surgery in the coming weeks. The Health Ministry has cleared compassionate‑use trials for eight patients, following mouse studies that...
Protein Biomarkers in Practice: Strategies to Reduce Drug Development Risk
Protein biomarkers are emerging as pivotal tools for reducing risk across the drug development lifecycle. Advances in high‑throughput proteomic platforms now allow real‑time functional insights, enabling stronger target validation, patient segmentation, and measurable efficacy signals. An eBook from GEN compiles...
Clene Secures FDA Pathway to File Accelerated‑Approval NDA for ALS Drug CNM‑Au8
Clene Inc. announced it will submit an accelerated‑approval New Drug Application for its ALS therapy CNM‑Au8 in the third quarter of 2026, following a FDA Type C meeting that said the company’s data could support the pathway. The filing hinges...
Delayed hCG Trigger Does Not Improve Oocyte Maturation Rate: Evidence From 9,319 IVF/ICSI Cycles Using Three Controlled Ovarian Hyperstimulation Protocols
A retrospective cohort of 9,319 first‑time IVF/ICSI cycles in China examined whether the proportion of dominant follicles at hCG trigger influences oocyte maturation. Across depot GnRHa, long GnRHa, and antagonist protocols, overall DFP showed no significant impact on maturation rates,...
FDA Clears Custom Titanium Cranial Implant for Skull Repair
The U.S. FDA granted 510(k) clearance to CGBIO’s EASYMADE TI, a patient‑specific titanium cranial and craniofacial implant made via laser powder‑bed fusion. The device is designed from each patient’s CT scan, manufactured in South Korea and shipped to U.S. hospitals within...
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Axsome Therapeutics held its first‑quarter 2026 earnings conference call on May 4, 2026. CEO Herriot Tabuteau, CFO Nick Pizzie and CCO Ari Maizel presented the company’s financial results, commercial strategy and pipeline milestones. The discussion featured forward‑looking statements about upcoming Phase 3 data and reaffirmed...
Accelerating Precision Medicine with Rapid Front-Line NGS-April 30, 2026
Memorial Sloan Kettering Cancer Center (MSKCC) has deployed Pillar Biosciences' oncoReveal® Nexus 21‑gene panel as a rapid front‑line next‑generation sequencing (NGS) test, dramatically shortening turnaround time versus its standard MSK‑IMPACT comprehensive profiling. The targeted panel, validated through the MSK‑REACT program,...
FDA Details Class I Catheter Recall over Safety Risk
The FDA has finalized a Class I recall for Cook Medical’s Centimeter, Aurous and Beacon Tip Sizing Catheters after an April early‑alert flagged a risk of cracking or breaking during vascular procedures. A Class I recall signals a reasonable probability of serious...
Kickoff Reception Launches SynBioBeta2026 Networking Opportunities
At 5 PM today in San Jose, #SynBioBeta2026 officially begins. The New Attendee Reception is the first event of the conference, and it's the perfect on-ramp: grab your lanyard, walk the venue, and start meeting the people you'll be running into...
Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics
UCB signed a definitive agreement to acquire privately held Candid Therapeutics for $2 billion upfront with up to $200 million in milestones. The deal, slated to close by late Q2 or early Q3 2026 pending antitrust clearance, adds a suite of T‑cell engager...
TRACS Enables Strain-Level Tracking of Microbial Transmission
A new algorithm called TRACS (Transmission Clustering of Strains) can differentiate closely related bacterial strains by analyzing single‑nucleotide polymorphisms. The tool was applied to SARS‑CoV‑2, Streptococcus pneumoniae and Plasmodium falciparum datasets, revealing detailed transmission networks across hospitals, populations and mother‑infant...
AAPS NBC 2026 To Highlight Predictive Tools in Drug Discovery with Opening Plenary
The AAPS National Biotechnology Conference 2026 will open with a plenary by Johns Hopkins professor Thomas Hartung, focusing on artificial intelligence and new‑approach methods (NAMs) that enhance predictive toxicology and human‑relevant models. Hartung will detail how AI‑driven in‑vitro systems, organoids...
Novo Nordisk’s Wegovy Head Start on Pills Forces Investors to Rethink Eli Lilly's GLP-1 Dominance
Novo Nordisk’s oral Wegovy pill, launched in January at $149 a month, quickly doubled patient intake for telehealth provider LifeMD and attracted tens of thousands of new GLP‑1 users. The strong start has forced investors to reassess Eli Lilly’s position after...
Blood as the Mirror of Aging
Recent research positions blood as both a diagnostic mirror and a therapeutic lever for aging. Multi‑omics studies show plasma proteins, metabolites, and extracellular vesicles reflect chronological and organ‑specific age, while heterochronic parabiosis and young plasma transfers demonstrate that youthful circulation...
Rett Syndrome Study Highlights Potential for Personalized Treatments
MIT researchers used 3‑D brain organoids derived from Rett patients to compare two common MECP2 mutations, R306C and V247X. The study revealed mutation‑specific structural, activity and network abnormalities, confirmed by patient EEG data. Targeted drug tests—an HDAC2 inhibitor for R306C...
One Hepatic Failure Case Sparks LLY vs Novo Debate
$LLY $NVO So one case of hepatic failure reported with $LLY Foundayo. To put this in perspective, with the injectables in this class, the reported hepatic incidents have been well under 1 in 100,000. Other oral GLP-1 agonists have also...
Deviation Capital Launches $300M Fund, Seeks Bio‑tech Founders at SynBioBeta
Deviation Capital just launched with a $300M fund target, and founding partner Dusan Perovic will be at #SynBioBeta2026 this week in San Jose looking for the next generation of founders to back. Deviation spun out of @TwoSigmaVC with a clear thesis:...
FDA Search for New CBER Head Focused on Small Group of Final Candidates
The U.S. Food and Drug Administration has narrowed its hunt for a new head of the Center for Biologics Evaluation and Research (CBER) to three or four finalists. CBER is the agency’s hub for overseeing vaccines, blood products, and emerging...
FDA Likely to Fast‑Track KRAS Drug for PR Boost
To try to offset this, I predict the FDA will approve the $RVMD KRAS drug in record time. Not just much quicker than usual. FDA needs a public relations win, and this will be their vehicle.
Gene Therapy Targets Childhood Blindness by Fixing Retinal Gene
Jean Bennett and Albert Maguire developed a gene therapy approach to correct a gene in the retina to treat childhood blindness. https://t.co/WJ99qvcUT1
NIH Study Finds Weekly Semaglutide Cuts Heavy Drinking by 41% When Paired With CBT
NIH scientists and Copenhagen University Hospital investigators found that a 26‑week course of weekly semaglutide injections alongside cognitive‑behavioral therapy lowered heavy‑drinking days by 41.1% in obese patients with alcohol‑use disorder, a 13.7‑point gain over placebo. The result suggests a new,...
New Toolkit Maps Human Ageing Hallmarks for Translation
🔬 Excited to share our new preprint on a translational toolkit for ageing research. We present a multi-modal approach to profile key hallmarks of human ageing, from immune function to mitochondrial activity and mTOR/autophagy. Our aim is to improve standardisation, reproducibility, biomarker...
Celcuity Bolsters ASCO‑highlighted Breast Cancer Drug Case
Celcuity strengthens case for ASCO-spotlighted breast cancer drug https://t.co/HdekunGXsu by @Lilah_Alvarado $CELC + 18% $NVS $AZN $RHHBY
Romanian 'Project Manhattan' Therapy Begins Human Trials to Reverse Aging
Romanian researchers have launched the first human trials of the experimental "Project Manhattan" therapy, which claims to reverse cellular aging and address dozens of age‑related diseases. The initiative arrives as the global longevity industry is valued at roughly $20 trillion, drawing...
Celcuity Strengthens Case for ASCO-Spotlighted Breast Cancer Drug
Celcuity announced that its experimental PI3K/mTOR inhibitor gedatolisib achieved statistically significant and clinically meaningful disease‑progression delays in two‑ and three‑drug combinations for patients with PIK3CA‑mutated, hormone‑receptor‑positive, HER2‑negative breast cancer. The data will be presented at the ASCO meeting in Chicago...
Latus Bio Secures $97 Million Series A to Scale Gene‑Therapy Manufacturing
Latus Bio announced a $97 million Series A financing, including a $43 million extension led by 8VC, to fund its proprietary AAV capsid platform and move two lead programs toward IND filing. The capital raise underscores investor confidence in scalable gene‑therapy solutions...
Passage Cuts 75% of Workforce After FDA Trial Design Request
Passage Bio announced it will cut roughly 75% of its workforce—about 18 of 24 employees—after the FDA rejected its proposed single‑arm registrational trial for PBFT02, a gene therapy targeting frontotemporal dementia with granulin mutations. The company expects to incur $3.3 million...
Latus Bio Raises $97M to Expand Gene Therapy Pipeline
Latus Bio announced a $97 million Series A financing round led by 8VC and DCVC Bio. The funding will accelerate its gene‑therapy pipeline focused on delivering adeno‑associated virus (AAV) capsids that can reach deep brain structures at dramatically lower doses....
IAM1363
Iambic Therapeutics of San Diego announced the initiation of a Phase 1 clinical trial for an oral covalent inhibitor targeting HER2‑mutant cancers. The molecule, identified through an AI‑guided high‑throughput screening campaign, binds irreversibly to the mutant HER2 kinase domain. Preclinical data...
Biotech Has a New Startup Model: Small Team, Big Check and Chinese Assets
A wave of biotech startups is emerging that forgos deep‑science platforms in favor of lean teams, mega‑size venture checks and strategic Chinese assets such as patient data, manufacturing capacity, and regulatory pathways. These companies raise $150‑$250 million in Series A or B...
UCB to Acquire Maker of Antibody Treatments for Autoimmune Diseases
UCB announced a definitive agreement to acquire a privately held biotech that develops monoclonal antibody treatments for autoimmune diseases. The target company’s portfolio includes candidates for rheumatoid arthritis, lupus and multiple sclerosis, complementing UCB’s existing immunology assets. Financial terms were...
Annual Grail Liquid Biopsy: Early Cancer Detection for the Wealthy
Everybody with a net worth over $5 million should do a Grail Liquid Biopsy every year. My wife, me and my parents all do it annually. $1k to do it. Every 3 years for $1-5 million net worth. Can give you super early detection...
German Lab Prints Tumors to Study Neutrophil Interactions
One of the cooler things I saw during my visit to Germany last week was this tumor printer. The company is using it to test how neutrophils affect the tumor microenvironment. https://t.co/jXzxDpj6nZ
Man Produces Sperm From Testicular Tissue Frozen as a Child in Breakthrough Trial
A 27‑year‑old man has produced mature sperm after his prepubertal testicular tissue, frozen at age 10 before chemotherapy for sickle‑cell disease, was re‑transplanted 16 years later. This is the first documented restoration of sperm production from cryopreserved prepubertal tissue in...
(Not) Getting Misled by Crystal Structures Part 6: Low Ligand Occupancies
A recent study re‑refined roughly 10,000 protein‑ligand structures from the PDB and found that while only 10% originally reported ligand occupancies at or below 0.9, re‑refinement raised that figure to 35%. Fragment‑sized ligands (<300 Da) were especially prone to occupancy loss,...
Funding Cuts and Visa Limits Spark US Brain Drain
#NIH funding cuts & visa crackdowns are driving away talented foreign researchers who normally would have flocked to the US, a @statnews.com survey shows. "It is going to cause a long-term brain drain," one US based researcher told @DrewQJoseph. ...
Choosing the Right CDMO for Long-Term Stability
Biotech firms must scrutinize contract development and manufacturing organizations (CDMOs) before committing to multi‑year projects. Dr. Patrick Meyer of Rentschler Biopharma outlines criteria such as transparent communication, accurate timelines, and a proven commercialization record. Technical expertise and a resilient supply chain...
NYU Study Finds Monocyte Aging Predicts Early Cognitive Depression
A New York University team discovered that epigenetic aging of monocytes—a type of white blood cell—predicts non‑somatic symptoms of depression in women, including those living with HIV. Analyzing 440 participants, the study suggests a blood‑based biomarker could enable earlier, objective...
Gene Therapy’s Evidence Problem—Lessons From Recent FDA Decisions
The FDA recently rejected REGENXBIO’s gene‑therapy candidate RGX‑121, citing an unvalidated biomarker as the primary endpoint and reliance on an external natural‑history control. The decision highlights a broader pattern of mixed regulatory outcomes for advanced therapeutics, with approvals like Sarepta’s...
Supreme Court Faces Emergency Request to Restore Mail‑Order Access to Abortion Pill
The U.S. Court of Appeals for the Fifth Circuit stayed the FDA's 2023 rule that permitted mifepristone to be prescribed via telemedicine and mailed to patients. In response, Danco Laboratories and generic maker GenBioPro petitioned the Supreme Court for an...